Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
2026-05-21 17:39:19 ET
B Group disclosed a purchase of 750,000 shares of ADMA Biologics (NASDAQ:ADMA) in a May 15, 2026, SEC filing, an estimated $11.84 million trade based on quarterly average pricing.
According to a May 15, 2026, SEC filing , B Group, Inc. increased its position in ADMA Biologics by 750,000 shares, with the estimated transaction value at $11.84 million based on the quarterly average price. The fund’s holding at quarter’s end stood at 3,207,542 shares, worth $28.90 million. The net position change, including share additions and price fluctuations, was a decrease of $15.93 million over the quarter.
ADMA Biologics, Inc. is a biopharmaceutical company specializing in plasma-derived therapies for immune deficiencies and infectious diseases. The company leverages a vertically integrated business model, controlling both plasma collection and product manufacturing to ensure supply chain reliability and product quality. With a focused portfolio and established distribution channels, ADMA Biologics addresses critical needs in the immunology and infectious disease markets, supporting its growth strategy and competitive positioning.
NASDAQ: ADMA
ADMA Trading
1.2% G/L:
$8.01 Last:
711,250 Volume:
$8.07 Open:
